The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer

Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer (NSCLC), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hao, Chong, Wei, Teng, Changcai, Yao, Yueliang, Wang, Xin, Li, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676111/
https://www.ncbi.nlm.nih.gov/pubmed/31222843
http://dx.doi.org/10.1111/cas.14113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676111/
https://www.ncbi.nlm.nih.gov/pubmed/31222843
http://dx.doi.org/10.1111/cas.14113

Ejemplares similares